Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INDP
STRONG SELLIndaptus Therapeutics, Inc. · Healthcare · United States · $348M · Avg Vol: $317K/d
8
StockRankGet insider-trade alerts
Q
26
V
21
M
34
P/E (TTM)
—
ROE
-931.8%
D/E
0.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)-43.0%
SMA 50SMA 200
Close
$2.04
RSI (14)
34.2
52W High
$10.57
From 52W High
0.2%
SCORE BREAKDOWN
Quality
26
ROIC
-552.8%0.6
ROE
-931.8%0.9
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-115.7%1.3
Piotroski
239.0
Int. Cover
—N/A
D/E Ratio
0.00x97.8
Current Ratio
2.34x44.4
Value
21
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
237.3x0.1
P/S
—N/A
Div Yield
—N/A
Momentum
34
52W High %
19%3.3
RS 6M
-33%28.7
SMA 50/200
1.05x74.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+89%70.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$348M
P/E (Forward)
-1.9x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INDP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INDP | Indaptus Therapeutics, Inc.(you) | $348M | 8 | STRONG SELL |
| UPB | Upstream Bio, Inc. | $349M | 8 | STRONG SELL |
| EDIT | Editas Medicine, Inc. | $399M | 8 | STRONG SELL |
| CMPX | Compass Therapeutics, Inc. | $373M | 7 | STRONG SELL |
| EVMN | Evommune, Inc. | $409M | 7 | STRONG SELL |
| DMAC | DiaMedica Therapeutics Inc. | $363M | 12 | STRONG SELL |
| LXEO | Lexeo Therapeutics, Inc. | $366M | 13 | STRONG SELL |
| FHTX | Foghorn Therapeutics Inc. | $285M | 6 | STRONG SELL |
| NMRA | Neumora Therapeutics, Inc. | $276M | 10 | STRONG SELL |
| LCTX | Lineage Cell Therapeutics, Inc. | $257M | 8 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%